Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Umeclidinium vs Glycopyrronium in COPD
NCT02236611Phase 4Completed
- Sponsor
- GSK
- Start
- Sep 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 4, randomised, open-label trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change From Baseline in Trough FEV1 at Day 85. Started Sep 2014; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02236611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02236611.